Serina Therapeutics signs deal for up to USD 25 million unregistered common stock sales to Roth Principal Investments

• Serina Therapeutics signed a common stock purchase agreement with Roth Principal Investments for up to USD 25 million of newly issued common stock.
• Shares may be issued in unregistered sales under Securities Act Section 4(a)(2) and Rule 506(b), subject to conditions including an effective resale registration statement.
• Issuance cap set at 5,077,554 shares, or 19.99% of outstanding stock, unless shareholder approval is obtained or pricing meets a USD 2.77 base price.
• Roth ownership limited to 4.99% of outstanding shares; pricing set at a discount to VWAP, with no upper limit on price.
• Proceeds earmarked for working capital and general corporate purposes; agreement runs up to 36 months from commencement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-26-000051), on August 27, 2026, and is solely responsible for the information contained therein.